ProPhase Labs Inc (PRPH)

[jobynimble]

8-K out…

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously reported on September 26, 2024, ProPhase Labs, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) on September 23, 2024, that the Company was not in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c)(2)(A) solely due to a vacancy on the audit committee (the “Audit Committee”) of the Company’s Board of Directors (the “Board”) resulting from Eleanor McBrier’s resignation from the Board as disclosed on Form 8-K filed on September 20, 2024.

On September 26, 2024, the Company received a notice from Nasdaq indicating that the Company was no longer in compliance with the audit committee requirements as set forth in Nasdaq Listing Rule 5605 and confirmed the Company’s opportunity to regain compliance within the cure period provided in Nasdaq Listing Rule 5605(c)(4), which was the earlier of the Company’s next annual meeting of stockholders or September 20, 2025, or if the next annual stockholders’ meeting was held before March 19, 2025, then the Company was required evidence compliance no later than March 19, 2025.

On June 23, 2025, the Company informed Nasdaq that on June 20, 2025, the Board appointed Carolina Abenante, Esq. to serve as an independent director to fill the existing vacancy on the Board and that the Board also intends to appoint Ms. Abenante to the Audit Committee effective July 19, 2025, the day following the Company’s 2025 Annual Meeting.

In response to the Company’s notification of Ms. Abenante’s appointment to the Board, on June 25, 2025, the Company received a letter from Nasdaq informing the Company that it was now in compliance with Nasdaq Rule 5605(c)(2) and that the matter is now closed.

Complete filing: https://www.sec.gov/ix?doc=/Archives/edgar/data/868278/000164117225017286/form8-k.htm